SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (158)2/4/2018 1:24:40 AM
From: Miljenko Zuanic1 Recommendation

Recommended By
ghmm

  Respond to of 294
 
<Might be you really do need to get to close to 100% receptor occupancy to really liven-up the immune system. >

Intratumoral route diminish possible off target effects, reduced systemic exposure, while increase "deep penetration". The problem is that it does reduce subject numbers that can be treated this way. For TRIL it may be right path. Finger crossed for those who hold.



To: Biomaven who wrote (158)2/4/2018 1:26:17 PM
From: semi_infinite   Respond to of 294
 
Same idea, different combo on mice.

med.stanford.edu


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News